Cougar Puberty Club Smart. Cheeky. Honest. Perimenopause, for real.

NPR: Everyone's Talking About Hormone Therapy. Should I Be On It? (Aug 2026)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: NPR (Shots - Health News) · Published: August 7, 2026 · Accessed: August 14, 2026

Visit the source ↗

Claims this source supports

  • The pendulum has swung on hormone therapy: medical groups now recommend it again for many patients, after years of cautioning against it (NPR reader Q&A, Dr. Mara Gordon, family physician, Camden NJ, Aug 7 2026).
  • The fear came from the Women's Health Initiative, stopped early in 2002 over apparent increased risks of heart disease, breast cancer, stroke, and pulmonary embolism; prescriptions then fell from ~22% of U.S. women over 40 in 1999-2000 to ~5% by 2010 (NPR citing study estimates).
  • Reanalyses of the WHI data led to a growing consensus that menopausal hormone therapy is much safer than doctors believed in the 2000s for women in their late 40s and 50s.
  • Systemic hormone therapy is primarily recommended to treat vasomotor symptoms (hot flashes, night sweats), can help prevent fractures in those at high risk of osteoporosis, and can treat genitourinary syndrome of menopause (vaginal estrogen); it is used for premature menopause after ovary removal.
  • Most major medical organizations - including the U.S. Preventive Services Task Force, ACOG, and the Menopause Society - do not recommend hormone therapy for longevity, heart health, or preventing chronic conditions; it is 'not the fountain of youth' and is not recommended for youthful-looking skin and hair.
  • There is genuine uncertainty about heart-disease prevention: research suggests HT near the menopausal transition (before 60 or within 10 years of menopause) may help prevent atherosclerosis, heart attacks, and strokes, but studies in women over 60 show no cardiovascular benefit or possibly increased risk (Dr. Karen Adams, Stanford).
  • Transdermal estrogen (patch) is generally less likely to cause blood clots than oral estrogen; people with a history of breast cancer, blood clots, heart attack, or stroke should have an in-depth conversation first, and nonhormonal options (certain antidepressants, fezolinetant) exist.
  • Per prescribing guidelines: take the minimum dose that effectively treats symptoms for the shortest possible duration; the decision is individual, based on medical history, symptoms, and values.